ENA Respiratory has dosed the first participants in Part B of its Phase IIa community study of INNA-051, a virus-agnostic, dry powder nasal spray. INNA-051 is designed to prime the natural antiviral host defences in the nose where common respiratory viruses like rhinovirus, flu, RSV and coronaviruses… Read More
A new study has revealed how an mRNA-based influenza vaccine reshapes immune responses at the cellular and molecular levels. By tracking germinal-centre (GC) activity and individual secreted antibody clonotypes for up to six months, researchers uncovered how vaccination drives the evolution and diversification of immune responses. … Read More
GSK has revealed that its mRNA seasonal influenza (flu) vaccine candidate has shown higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines. The Phase II data were presented at the OPTIONS XIII Conference for the Control of… Read More
African biopharmaceutical company Minapharm Group will receive up to $16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate. The investment is part of efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on… Read More
The world-first trial of a fridge-free tetanus-diphtheria vaccine has produced encouraging results that could improve access worldwide to crucial treatments. Around half of vaccines are wasted globally each year, according to the World Health Organization, because of temperature changes during storage and transport. Fridge-free vaccines… Read More
Following Health Canada’s authorisation, the first participants have been vaccinated in Moderna’s Phase I clinical study evaluating mRNA-1469, an mRNA vaccine to prevent Bundibugyo ebolavirus (BDBV). “Vaccinating the first participants with mRNA-1469 marks an important milestone in advancing a vaccine candidate against Bundibugyo ebolavirus, for which no… Read More
Antiviral therapeutics company Cocrystal Pharma has announced a $5 million investment from OPKO Health, a longtime investor in the company. The investment will support Cocrystal as it advances its lead norovirus programme towards Phase Ib topline data later this year. Under the terms of the agreement,… Read More
The 2025 Global Vaccines Market Report from the World Health Organization (WHO) reports a total financial value of $66 billion in 2024, though this is predicted to grow to $227.89 billion by 2034 due to the rising prevalence of infectious diseases and increasing demand for immunisation programmes. Read More
This eBook, sponsored by Emulate, explores the factors having the greatest influence on today’s vaccine discovery, from viral outbreaks to national health policy, and reviews the progress in vaccine development since the Covid-19 pandemic.
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a nanoparticle vaccine showed potential to protect from a ‘tripledemic’. Elsewhere, could… Read More
A single-shot vaccine under development at the University at Buffalo in the US could protect against flu, Covid-19 and respiratory syncytial virus (RSV) simultaneously. In a study published in Science Advances, the researchers found that their three-in-one vaccine triggered protective immunity against all three respiratory… Read More
A new agreement is set to advance a vaccine for ovarian cancer which has shown 40% cancer-free survival rates. Biotechnology company CellxLife has entered an agreement with Mayo Clinic for the dendritic cell vaccine, which reported the 40% 10-year cancer-free survival rate in a Phase I Mayo Clinic study… Read More
A novel ‘universal’ vaccine has been engineered to provide protection from thousands of variants in one single dose. Results from a first-in-human clinical trial, published in the Journal of Infection, show the vaccine protected participants from multiple Sarbeco coronaviruses, a large group of viruses including SARS-CoV-2, as… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More
Lilly has reached an acquisition agreement with LimmaTech Biologics AG, a Swiss clinical-stage biotech company, for up to $780 million. The buy-out was part of a spending spree by Lilly on company pipelines that address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens… Read More